Extract of stinging nettle roots (Bazoton®-uno) in long-term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo-controlled multicenter study after 12 months;Brennnesseltrockenextrakt (Bazoton®-uno) in der langzeittherapie des benignen prostatasyndroms (BPS): Ergebnisse einer randomisierten, doppelblinden, placebokontrollierten multicenterstudie über 12 monate

Urologe - Ausgabe A

Volumn 43, Issue 3, 2004, Pages 302-306

  Schneider, T ^a   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Benign prostatic syndrome (BPS); IPSS, LUTS; Phytotherapy

Indexed keywords

PLACEBO; PLANT EXTRACT; URTICA EXTRACT;

ADULT; AGED; ARTICLE; BENIGN PROSTATIC SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HERBAL MEDICINE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PARAMETER; PHASE 4 CLINICAL TRIAL; PHYTOTHERAPY; PLANT ROOT; PROSTATISM; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOM; URINARY TRACT INFECTION; URTICA DIOICA; CHEMISTRY; HOSPITALIZATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PROSTATE HYPERTROPHY; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYTOTHERAPY; PLACEBO EFFECT; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICA DIOICA;

EID: 3042696595     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0532-7     Document Type: Article

References (18)

1. Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe B 40: 437-443
2. Becker H, Ebeling L (1988) Konservative Therapie der benignen Prostatahyperplasie (BPH) mit Cernilton. Urologe B 28: 301-306
3. Berges RR, Windeler J, Trampisch H et al. (1995) Randomized, placebo-controlled, double-blind clinical trial of beta sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529-1532
4. Buck AC, Cox R, Rees RWM et al. (1990) Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract Cernilton. Br J Urol 66: 398-404
5. Carrara JC, Raynaud J-P, Koch G et al. (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. Prostate 29; 231-240
6. Dathe G, Schmidt H (1987) Phytotherapie der benignen Prostatahyperplasie: Doppelblindstudie mit Extractum Radicis Urticae (ERU). Urologe B 27: 233-226
7. Debruyne F, Koch G, Boyle P et al. (2002) Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized, international study. Eur Urol 41: 497-507
8. Dreikorn K, Berges RR, Pientka L, Jonas U (2002) Phytotherapie bei BPH. Aktuelle evidenzbasierte Bewertung. Urologe A 41: 447-451
9. Engelmann U, Boos G, Kreis H (1996) Therapie der benignen Prostatahyperplasie mit Bazoton® Liquidum. Urologe B 36: 287-291
10. Fischer M, Wilbert D (1992) Wirkprüfung eines Phytopharmakons zur Behandlung der benignen Prostatahyperplasie III. Zuckschwerdt, München, S 79-84
11. Goepel M, Hecker U, Krege S, Ruebben H, Michel MC (1999) Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 38: 208-215
12. Goepel M, Dinh L, Mitchell A, Schaefers RF, Ruebben H, Michel MC (2001) Do saw palmetto extracts block human α1-adrenoceptor subtypes in vivo? Prostate 46: 226-232
13. Klippel KF, Hiltl D-M, Schipp B (1997) A multicentric placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80: 427-432
14. Kuznetzow DD, Gerber GS, Burstein JD (2001) Randomized, double blind, placebo, placebo-controlled study of saw palmetto in men with lower urinary tract symptoms (LUTS). J Urol 58: 960-964
15. Metzker M, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparates bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36: 292-300
16. Sökeland J, Albrecht J (1997) Kombination aus Sabal- und Urticaextrakt mit Finasterid bei BPH (Stadium I-II nach Alken). Urologe A 36: 327-333
17. Vontobel HP, Herzog R, Rutishauser GH (1985) Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologe A 24: 49-51
18. Wagner H, Willer F (1990) Chemie und Pharmakologie von Urtica-Präparaten - Antiphlogistische und immunmodulierende Wirkung. Ngm 3: 309-312